Twice daily i.p. administration (bid) of 5 and 15 mg/kg AZD-4573 resulted in 97% and 100% tumor growth inhibition, respectively, for MV-4-11 and 65% inhibition, for both doses, against Nomo-1 based AML xenograft mouse models, along with reductions in pS2, MCL-1 levels and increase in Caspase-3 cleavage. This evidence concerns the gene MCL1 and acute myeloid leukemia.